Key result
Paracetamol demonstrated comparable efficacy to ibuprofen and indomethacin for closing patent ductus arteriosus in premature newborns, while being associated with fewer adverse effects such as gastrointestinal hemorrhage and renal intolerance.
Why the study?
Patent ductus arteriosus is associated with multiple complications and high neonatal mortality, prompting evaluation of the efficacy and benefits of paracetamol compared to ibuprofen and indomethacin.
Does paracetamol improve closure of patent ductus arteriosus in premature newborns?
Population
Premature newborns with patent ductus arteriosus
Comparison
Paracetamol vs ibuprofen, indomethacin, placebo, or nonintervention
Design
Systematic review
Authors
Loading...
Supports paracetamol as first-line for PDA closure in preterm infants; reinforces Level 1 evidence for safer NSAID alternatives.
Systematic Review
Does paracetamol improve closure of patent ductus arteriosus in premature newborns?
Paracetamol is a promising and effective pharmacological alternative to classic NSAIDs for the closure of patent ductus arteriosus in premature newborns, offering a comparable efficacy with a better safety profile.
Resende et al. (2022) conducted a systematic review in Patent ductus arteriosus. Paracetamol vs. Ibuprofen, indomethacin, placebo, or non-intervention was evaluated on Closure of patent ductus arteriosus. Paracetamol demonstrated comparable efficacy to ibuprofen and indomethacin for closing patent ductus arteriosus in premature newborns, while being associated with fewer adverse effects such as gastrointestinal hemorrhage and renal intolerance.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: